Pegasystems Inc.
released a new offering for the Life Sciences market. The AdverseEvent Case Processing solution revolutionizes how organizations collect, manage, and analyze adverse events both during and after clinical trials, thereby shortening the timeline for conducting successful clinical trials and improving the post-approval management of safety information.
All clinical trials and marketed products have the potential to produce adverse events ranging from minor to serious in nature, even when available to the general public. Adverse events categorized as "serious," or something that could result in initial or prolonged hospitalization, death, etc., must be reported to regulatory authorities immediately. In a highly competitive industry where patent expirations and rising drug development costs are pressuring bottom lines, life sciences companies need better operational efficiency to adapt to changing regulations and reduce costs. The Adverse Event Case Processing solution improves critical stages of pharmacovigilance operations. New automation and operational efficiencies that leverage built-in business process management capabilities, include:
This new solution deploys rapidly by using advanced technologies to quickly leverage existing adverse event processing rules and requirements and can produce dynamic specialized documentation to help ensure compliance in a validated environment.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.